In the clinical trial named EPINOV, scientists of the Institute De Neuroscience Des Systems (INS) in France are looking at how far a computer model of the epileptic brain can improve the rate of epilepsy surgeries. They have reported on the approach and the clinical trial in their research paper published in the journal Science.
Now, the world’s first minimally invasive brain pacemaker utilizes a pioneering procedure that uses subcutaneous electrodes positioned outside the cranium to suppress epileptic seizures in patients with focal epilepsy that is resistant to drug therapy.
This study aimed to explore the association between epilepsy and cognitive impairment, and to determine factors associated with cognitive impairment in older people with epilepsy.
A new study will investigate whether smartwatches could help predict seizures for people living with epilepsy
Pediatric Epilepsy
International research teams have uncovered a new cause for pediatric seizures: mosaicism, a condition in which cells within the same individual have different genetic compositions.
Pediatric Epilepsy
Researchers have developed a prediction model that determines which newborn babies are likely to experience seizures in the Neonatal Intensive Care Unit (NICU). This model could be incorporated into routine care to help the clinical team decide which babies will need electroencephalograms (EEGs) and which babies can be safely managed in the Neonatal Care Unit without monitoring through EEGs.
Featuring the work of former CURE Epilepsy Grantee Dr. Brian Litt.
Penn neurologist Brian Litt’s work on implantable devices for recording and altering brain activity has led to new ways to treat and diagnose epilepsy.
The study, revealed sodium selenate to have a long-lasting effect (after months of stopping the medication) in reducing the frequency of seizures (and in 30% of cases stopping them altogether) and improving other aspects of epilepsy such as memory, learning and sensor-motor functioning.
Pediatric Epilepsy
Our findings that 40% of patients with recurrent pediatric-onset epilepsy could achieve long-term seizure freedom and that all patients with a second seizure recurrence remained seizure free suggest that ASM may be withdrawn for a second time after carefully stratifying clinical risk.
